XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized $ 55,902 $ 36,161
Drug Product Revenue, Net [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 24,486 2,109
Drug Product Revenue, Net [Member] | Japan [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized   1,700
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 1,200  
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Japan [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized (2,205) 1,732
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Europe [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 1,021 377
Drug Product Revenue, Net [Member] | AstraZeneca Agreements [Member] | U.S. [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized $ 25,670